In a recent development that has raised serious concerns, a Health Canada report has revealed some alarming practices at private plasma clinics, specifically Grifols. The report highlights how the company repeatedly overlooked crucial donor screening protocols, putting the safety of the blood supply at risk. This news comes at a time when blood safety advocates are calling for stricter regulations and oversight, especially given the recent deaths of two individuals after plasma donations at Grifols locations in Winnipeg.
Donor Screening Lapses
One of the most concerning findings in the report is Grifols' handling of donors at risk for Creutzfeldt-Jakob disease (CJD). Despite clear guidelines for deferring such donors indefinitely, Grifols lifted deferrals for individuals with a family history of CJD and those exposed to the rare variant associated with "mad cow disease." This decision, made after changing exclusion criteria in March 2025, could have potentially compromised the safety of the blood supply.
What makes this particularly fascinating is the stringent screening protocols typically in place for CJD. The disease, known for its rapid progression and always-fatal outcome, is feared by many. However, the report suggests that Grifols' actions may have exposed the blood supply to this risk.
Capacity and Supervision Issues
In addition to donor screening concerns, the report also highlights operational issues at Grifols' Winnipeg centres. On January 3, 2025, one of the centres operated with 119 donors, including new applicants, while only one physician substitute was available. This exceeded the daily maximum capacity of 100 donors per physician substitute, as specified by the report.
Furthermore, on the following day, the same centre collected plasma and assessed donors' eligibility without any physician substitute on site. This raises questions about the level of supervision and the potential risks associated with such practices.
Grifols' Response and Expert Opinion
In response to the report, Grifols issued a statement claiming that they are addressing the issues identified by Health Canada, while maintaining that these practices never posed a risk to donor or patient safety. The company also stated that no plasma units were collected from donors meeting the exclusion criteria.
Dr. Valerie Sim, an expert in prion diseases like CJD, offered some insight into the situation. She emphasized that while screening for CJD is stringent due to the disease's severity, it's highly unlikely that CJD has contaminated the blood supply. There are no records of the two most common types of CJD being transmitted by blood, and the rare variant associated with "mad cow disease" has not been seen since 2016.
Broader Implications and Future Steps
The report's findings have prompted blood safety advocates to call for stronger action from Health Canada. Personal injury lawyer Gary Will suggested that the agency should consider suspending Grifols' license or taking legal action against the company. Sara Labelle, a medical laboratory technologist, warned of the potential for another tainted blood crisis if these issues are not addressed.
In conclusion, the Health Canada report sheds light on some alarming practices at Grifols, raising questions about donor safety and the company's operational procedures. While Grifols maintains that their actions were safe, the report's findings suggest otherwise. This situation highlights the need for rigorous oversight and regulation in the plasma donation industry to ensure the safety of donors and the blood supply. As we move forward, it's crucial to address these concerns to prevent any further incidents and maintain public trust in the blood donation system.
